Key clinical point: Improved renal cell carcinoma survival appears to be attributable to improvements in therapy rather than increased diagnosis of early-stage disease.
Major finding: 5-year survival increased from 9.8% in 2004 to 13.2% in 2010 for patients with distant metastatic disease.
Study details: Retrospective analysis of data from the National Cancer Database on 262,597 patients diagnosed with RCC from 2004 through 2015.
Disclosures: No study funding source was reported. Dr. Patel and coauthors reported having no conflicts of interest to disclose.
Patel HD et al. Eur Urol Oncol. 2018 Sep 25. doi: 10.1016/j.euo.2018.08.023
This Week's Must Reads
RNA expression offers potential biomarker in hemophilia A, Niloofar N et al. Hematology. 2019;24(1):255-62
Caplacizumab speeds platelet normalization, Scully M et al. N Engl J Med. 2019 Jan 9. doi: 10.1056/NEJMoa1806311
Remote area of Canada provides pool for genetic research, Scully M-F et al. Transfus Apher Sci. 2018 Dec;57(6):713-6
Can web tools replace pharmacokinetic analysis in hemophilia A?, Nagao A et al. Thromb Res. 2019 Jan;173:79-84
BSH issues recommendations for glucocorticoid use in ITP, Hill QA et al. Br J Haematol. 2019 Jan 4. doi: 10.1111/bjh.15735
Must Reads in Renal Cell Carcinoma
One-fourth of placebo arm experience adverse events in RCC trials, Chacón M et al. JAMA Network Open. 2018 Dec 7. doi: 10.1001/jamanetworkopen.2018.5617
Strong link found between RCC and melanoma, Kim KB et al. Cancer Epidemiol. 2018 Oct 19;57:80-4
Apo B/A1 predicts survival in metastatic renal cell carcinoma, Zhang F et al. Urol Oncol. 2018 Nov 30. doi: 10.1016/j.urolonc.2018.11.010
RCC patients with brain-only metastases may benefit from cytoreductive nephrectomy, Daugherty M et al. Urol Oncol. 2018 Dec 5.doi: 10.1016/j.urolonc.2018.10.021
Lower concentration of pazopanib linked with less toxicity, Noda S et al. Clin Genitourin Cancer. 2018 Dec 7. doi: 10.1016/j.clgc.2018.12.001